Biotechnology company MabVax Therapeutics has received a $1.75 million contract from the U.S. National Cancer Institute (NCI) to support development of its novel pancreatic cancer PET imaging agent.
MabVax is developing a PET imaging agent for the diagnosis, staging, and treatment assessment of pancreatic cancer. The product, an antibody fragment linked to a radioactive tracer, is based on the company's discovery of a human antibody that binds to a cancer antigen expressed in pancreatic cancer, according to the firm.
The NCI contract, No. HHSN261201300060C, was received under the NCI's Small Business Innovation Research Technology Program (SBIR). MabVax will receive $1.75 million over the next three years subject to satisfactory progress and continued availability of funds in the SBIR program, according to the firm.
